Combined treatment using adoptive cell therapy, extended pharmacokinetic IL-2, and tumor-specific antibodies leads to cures of established B16F10 tumors and extended in vivo T cell survival

Antzeko izenburuak

• Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2
  nork: Zhu, Eric F., et al.
  Argitaratua: (2015)
• Anti-tumor antibodies can drive therapeutic T cell responses
  nork: Wittrup, K. Dane
  Argitaratua: (2017)
• Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells
  Argitaratua: (1982)
• Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen
  nork: Chekmasova, Alena A., et al.
  Argitaratua: (2010)
• Induced sensitization of tumor stroma leads to eradication of established cancer by T cells
  nork: Zhang, Bin, et al.
  Argitaratua: (2007)